drugset / Trial / NCT05061550
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Timeline
- Start
- 2022-04-14
- Primary completion
- 2030-05-28
- Completion
- 2030-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Datopotamab deruxtecan | Monoclonal antibody | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | FALBIKITUG | Monoclonal antibody | — | Intravenous |
| Subject | Monalizumab | Monoclonal antibody | — | Intravenous |
| Subject | Oleclumab | Monoclonal antibody | — | Intravenous |
| Subject | Rilvegostomig | Other / unclassified | — | Intravenous |
| Subject | Volrustomig | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |